Last reviewed · How we verify
Medical Standard of Care for ITP — Competitive Intelligence Brief
phase 3
Immunology / Hematology
Small molecule
Live · refreshed every 30 min
Target snapshot
Medical Standard of Care for ITP (Medical Standard of Care for ITP) — Amgen. This represents the established standard treatment approach for immune thrombocytopenia (ITP), which typically aims to increase platelet counts through immune modulation or platelet production stimulation.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Medical Standard of Care for ITP TARGET | Medical Standard of Care for ITP | Amgen | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Medical Standard of Care for ITP CI watch — RSS
- Medical Standard of Care for ITP CI watch — Atom
- Medical Standard of Care for ITP CI watch — JSON
- Medical Standard of Care for ITP alone — RSS
Cite this brief
Drug Landscape (2026). Medical Standard of Care for ITP — Competitive Intelligence Brief. https://druglandscape.com/ci/medical-standard-of-care-for-itp. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab